Related Experiment Video

Updated: May 22, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Statins and cancer: current and future prospects

Maja Osmak1

  • 1Ruđer Bošković Institute, Bijenička cesta 54, HR-10000 Zagreb, Croatia. osmak@irb.hr

Cancer Letters
|May 1, 2012
PubMed

Insights

Statins, cholesterol-lowering drugs, show anticancer potential beyond lowering cholesterol. Preclinical studies suggest combining statins with chemotherapy may improve cancer treatment effectiveness for specific tumor types.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Statins are primarily known as inhibitors of 3-hydroxy-methylglutaryl (HMG) CoA reductase, widely used for cholesterol reduction.
  • Emerging evidence suggests statins possess significant anticancer activities independent of their lipid-lowering effects.

Purpose of the Study:

  • To review the in vitro effects of statins on cancer.
  • To explore potential molecular anticancer mechanisms of statins.
  • To critically evaluate the role of statins in cancer prevention and their combination with chemotherapy.

Main Methods:

  • Review of in vitro studies on statin effects in cancer.
  • Analysis of molecular mechanisms underlying statin-induced anticancer activity.
  • Critical discussion of clinical and preclinical data on statins in cancer prevention and treatment.

Main Results:

  • Statins demonstrate anticancer effects in preclinical models.
  • Potential molecular mechanisms include pathways involved in cell proliferation, apoptosis, and angiogenesis.
  • Preclinical data suggest statin-chemotherapy combinations are promising for certain cancers.

Conclusions:

  • Statins exhibit anticancer properties through various molecular pathways.
  • While clinical data on cancer prevention are limited, preclinical evidence supports their therapeutic potential.
  • Combining statins with conventional chemotherapeutics represents a promising strategy for enhancing cancer treatment efficacy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...